#1 Clinical Trials Search in Europe

Cpft Trifluoroacetate

A groundbreaking clinical trial is underway to investigate the potential of Cpft Trifluoroacetate in improving live birth rates for women under 37 years old undergoing Intracytoplasmic Sperm Injection (ICSI). This study aims to evaluate the effectiveness of supplementing culture media with Cpft during the pre-ICSI incubation of oocytes and preimplantation embryo development. The trial, named FERTICSI, offers hope for couples struggling with infertility and seeking assisted reproductive technologies.

Table of Contents

What is CPFT Trifluoroacetate?

CPFT Trifluoroacetate is a new medication being studied to improve the success rates of a specific type of assisted reproductive technology called Intracytoplasmic Sperm Injection (ICSI). ICSI is a procedure where a single sperm is directly injected into an egg to help with fertilization.[1]

How CPFT Trifluoroacetate Works

CPFT Trifluoroacetate is a special type of molecule called a hexapeptide. It mimics a part of a sperm protein called Fertilin β, which is important for the sperm and egg to interact during fertilization. When added to the culture medium (the liquid where eggs and embryos are kept during IVF), CPFT Trifluoroacetate has shown promising results in improving various aspects of assisted reproduction.[1]

Potential Benefits of CPFT Trifluoroacetate

Research has shown that CPFT Trifluoroacetate may offer several benefits in assisted reproduction:

  • Increases the maturation of human eggs in the laboratory
  • Improves the genetic health (ploidy) of human eggs
  • Enhances the development of embryos before implantation in both mice and humans

These improvements could potentially lead to higher success rates in fertility treatments.[1]

Current Clinical Trial: FERTICSI Study

A clinical trial called FERTICSI is currently underway to study the effects of CPFT Trifluoroacetate on improving live birth rates after ICSI. This study is being conducted in multiple centers and involves women under 37 years of age who are undergoing fertility treatment.[1]

Who is Eligible for the FERTICSI Study?

The study includes couples who meet the following criteria:

  • Require Medically Assisted Reproduction
  • Are eligible for ICSI
  • Women aged 18 to 36 years
  • Men aged 18 to 58 years
  • Affiliated with a Social Security system

Some conditions that would exclude participation include early menopause, certain medical conditions, or the need for egg or sperm donation.[1]

Study Objectives and Endpoints

The main goal of the FERTICSI study is to see if adding CPFT Trifluoroacetate to the culture medium can improve the rate of live births after ICSI. The study will also look at several other important factors, including:

  • The quality and development of embryos
  • Pregnancy rates and miscarriage rates
  • The health of babies during pregnancy and after birth
  • The development of children up to one year old

These outcomes will help researchers understand the full impact of CPFT Trifluoroacetate on fertility treatment and child health.[1]

How CPFT Trifluoroacetate is Administered

It’s important to note that CPFT Trifluoroacetate is not directly given to patients. Instead, it is added to the culture medium where eggs and embryos are kept during the ICSI procedure. The maximum duration of exposure is 6 days, which covers the time from egg retrieval to embryo transfer or freezing.[1]

Future Implications and Considerations

If the FERTICSI study shows positive results, CPFT Trifluoroacetate could become an important addition to fertility treatments, potentially increasing the success rates of ICSI procedures. However, it’s crucial to remember that the study is still ongoing, and more research will be needed to fully understand the long-term effects and benefits of this treatment.[1]

As with any medical treatment, especially those involving assisted reproduction, it’s essential to discuss all options, potential benefits, and risks with your healthcare provider. They can provide personalized advice based on your specific situation and the most up-to-date research findings.

Aspect Details
Study Name FERTICSI: Improvement of Live Babies Rates After ICSI, Using cpFT
Main Objective Improve live birth rates after ICSI using Cpft Trifluoroacetate supplementation
Participant Age Women: 18-36 years, Men: 18-58 years
Treatment Cpft Trifluoroacetate added to culture medium for oocytes and embryos
Primary Endpoint Live baby birth rate after first embryo transfer
Follow-up Period Up to one year after birth
Key Assessments Embryo quality, pregnancy rates, baby health and development

FAQ

  • What is the main goal of the FERTICSI clinical trial? The main goal of the FERTICSI clinical trial is to demonstrate an improvement in live birth rates after ICSI by supplementing the culture medium with Cpft Trifluoroacetate (1µM) during oocyte incubation and embryo development for women under 37 years of age.
  • Who is eligible to participate in this clinical trial? Eligible participants include couples requiring Medically Assisted Reproduction (AMP) and eligible for ICSI. Women must be between 18 and 36 years old, while men should be between 18 and 58 years old. Participants must be affiliated with a Social Security system.
  • How is Cpft Trifluoroacetate used in the trial? Cpft Trifluoroacetate is added to the culture medium (CSCM-C) used for incubating oocytes before ICSI and during the preimplantation development of embryos. It is not directly administered to patients but used to supplement the culture environment for the eggs and embryos.
  • What are some of the secondary objectives of the study? Secondary objectives include evaluating the quality of embryonic culture, assessing embryo development kinetics, examining blastocyst quality, and evaluating the health and development of babies born from the treatment up to one year old.
  • How long will the study follow the outcomes? The study will follow outcomes from the initial treatment through pregnancy, birth, and up to one year after the baby is born. This includes monitoring the baby's health and development during pregnancy, at birth, and through pediatric consultations in the first year of life.

Ongoing Clinical Trials on Cpft Trifluoroacetate

  • Study on Improving Live Birth Rates in Women Under 37 with Infertility Using cpFT During ICSI

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • ICSI (Intracytoplasmic Sperm Injection): A fertility treatment where a single sperm is injected directly into an egg to facilitate fertilization.
  • Cpft Trifluoroacetate: A peptide that mimics the binding site of a sperm membrane protein called Fertilin β, which is involved in gamete interaction. It is being studied for its potential to improve in vitro maturation and embryonic development.
  • Oocyte: An immature egg cell in the ovary, which can develop into a mature egg (ovum) ready for fertilization.
  • Blastocyst: An early stage embryo, typically 5-6 days after fertilization, consisting of about 100 cells.
  • Vitrification: A fast-freezing technique used to preserve eggs, sperm, or embryos for future use in fertility treatments.
  • Beta hCG: A hormone produced during pregnancy, often measured to confirm and monitor early pregnancy.
  • Implantation: The process by which an embryo attaches to the uterine wall, marking the beginning of pregnancy.
  • Metaphase II oocytes: Mature egg cells that have reached the stage of development where they are ready for fertilization.
  • Preimplantation: The period of embryo development before it implants in the uterus, typically the first 5-6 days after fertilization.
  • Gardner classification: A system used to grade the quality of blastocysts based on their expansion, inner cell mass, and trophectoderm.

References

  1. http://clinicaltrials.eu/trial/study-on-improving-live-birth-rates-in-women-under-37-with-infertility-using-cpft-during-icsi/